Indoco Remedies' stock rose 7% to an eight-month high of Rs 414.85 on Thursday during intraday trading as investors bet on further increase in its margins.
It reached its highest level since March 2022, when the pharmaceutical company's stock was traded. As opposed to the S&P BSE Sensex's 0.35 percent increase over the preceding week, it increased by 17%. Before that, on January 3, 2022, the stock reached a 52-week high of Rs 459.
54% of sales were made using domestic formulations. Primary treatments include those for the respiratory, immune, gastrointestinal, stomatological, and vitamin systems. Revenues came from formula exports, which comprised 41% of total sales, while APIs provided 4% and CRAMS contributed the remaining 20%.
Indoco Remedies reported a 12% year-over-year (YoY) improvement in revenues for July to September (Q2FY23), totaling Rs 433 crore. EBITDA increased by 1.7% YoY to Rs 88 crore, while margins were at 20.3%. In the meantime, profit after tax increased YoY by 19% to Rs 49.7 crore.
Related Tags
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Securities Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2024, IIFL Securities Ltd. All Rights Reserved
www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.
Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
